Notice of Interim Results

RNS Number : 1493C

Oxford Biomedica PLC

27 August 2008

 



FOR IMMEDIATE RELEASE	27 AUGUST 2008

OXFORD BIOMEDICA PLC

NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2008

Oxford, UK - 27 August 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces that it will be releasing its interim results for the six months ended 30 June 2008 on Friday, 29 August 2008.

Analyst meeting: An analyst briefing will be held at 10:00 am on 29 August at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE. 

Web cast: Simultaneously to the analyst briefing at 10.00 am, there will be a live audio web cast of the results presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09.50 am) before the start of the briefing. This will also be available for replay shortly after the presentation.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  Andrew Wood, Chief Financial Officer Nick Woolf, Chief Business Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
NM Rothschild & Sons: Lynn Drummond/ Christopher Bath	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Holly Griffiths/ Katja Stout/ Claire Mosley College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. TroVax® is the Company's therapeutic vaccine, which is in clinical development for multiple solid cancers. The product is licensed to sanofi-aventis for global development and commercialisation. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NOREDLFLVVBXBBB